Insmed Incorporated (NASDAQ:INSM) and Nabriva Therapeutics plc (NASDAQ:NBRV) are two firms in the Biotechnology that compete against each other. Below is a comparison of their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Nabriva Therapeutics plc||2||44.51||N/A||-2.10||0.00|
Table 1 shows top-line revenue, earnings per share and valuation of the two companies.
Table 2 demonstrates the return on equity, net margins and return on assets of Insmed Incorporated and Nabriva Therapeutics plc.
|Net Margins||Return on Equity||Return on Assets|
|Nabriva Therapeutics plc||0.00%||-162.3%||-117.6%|
Risk and Volatility
Insmed Incorporated has a 2.76 beta, while its volatility is 176.00% which is more volatile than S&P 500. Nabriva Therapeutics plc’s 2.4 beta is the reason why it is 140.00% more volatile than S&P 500.
Insmed Incorporated’s Current Ratio is 4.8 while its Quick Ratio is 4.7. On the competitive side is, Nabriva Therapeutics plc which has a 5.6 Current Ratio and a 5.6 Quick Ratio. Nabriva Therapeutics plc is better positioned to pay off short and long-term obligations compared to Insmed Incorporated.
In next table is given Insmed Incorporated and Nabriva Therapeutics plc’s ratings and recommendations.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Nabriva Therapeutics plc||0||0||0||0.00|
The consensus target price of Insmed Incorporated is $45.2, with potential upside of 177.98%.
Insider & Institutional Ownership
Roughly 94.4% of Insmed Incorporated shares are held by institutional investors while 49.6% of Nabriva Therapeutics plc are owned by institutional investors. Insiders held 1.1% of Insmed Incorporated shares. Competitively, insiders own roughly 0.61% of Nabriva Therapeutics plc’s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Nabriva Therapeutics plc||-0.21%||-1.86%||9.45%||24.35%||-11.71%||62.67%|
For the past year Insmed Incorporated’s stock price has bigger growth than Nabriva Therapeutics plc.
Insmed Incorporated beats Nabriva Therapeutics plc on 5 of the 8 factors.
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The companyÂ’s lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.
Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of novel antibiotics to treat serious bacterial infections with a focus on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, a novel semi-synthetic pleuromutilin antibiotic for systemic administration in humans. The companyÂ’s product, lefamulin is being studied in two registrational Phase 3 clinical trials in patients with moderate to severe community-acquired bacterial pneumonia. It is also developing lefamulin that has completed Phase 2 clinical trial for the treatment of acute bacterial skin and skin structure infections, as well as in preclinical studies for antibacterial activity against various gram-positive bacteria, gram-negative bacteria, and atypical bacteria, including multi-drug resistant strains. In addition, the company is developing BC-7013, a topical pleuromutilin product candidate, which has completed a Phase 1 clinical trial for the treatment of various gram-positive infections, including uncomplicated skin and skin structure infections. Nabriva Therapeutics plc was founded in 2006 and is based in Dublin, Ireland.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.